These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38691868)

  • 1. EP300 through upregulating the expression of vimentin to promote the progression of chordoma.
    Wen L; Xie B; Li H; Huang J; Shi Y; Tao Y; Chen Y
    Neurosurg Focus; 2024 May; 56(5):E17. PubMed ID: 38691868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
    Mahmud Z; Asaduzzaman M; Kumar U; Masrour N; Jugov R; Coombes RC; Shousha S; Hu Y; Lam EW; Yagüe E
    Biochem Pharmacol; 2019 May; 163():391-403. PubMed ID: 30862505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Therapeutic Potential of SOX9 in Chordoma.
    Chen H; Garbutt CC; Spentzos D; Choy E; Hornicek FJ; Duan Z
    Clin Cancer Res; 2017 Sep; 23(17):5176-5186. PubMed ID: 28606919
    [No Abstract]   [Full Text] [Related]  

  • 4. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC00662 triggers malignant progression of chordoma by the activation of RNF144B via targeting miR-16-5p.
    Wang CB; Wang Y; Wang JJ; Guo XL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1007-1022. PubMed ID: 32096180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.
    Zhang H; Yang K; Ren T; Huang Y; Tang X; Guo W
    Cell Death Dis; 2018 Jun; 9(6):680. PubMed ID: 29880900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
    Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma.
    Gulluoglu S; Sahin M; Tuysuz EC; Yaltirik CK; Kuskucu A; Ozkan F; Sahin F; Ture U; Bayrak OF
    Oncol Res; 2017 Aug; 25(7):1177-1188. PubMed ID: 28247842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
    Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
    Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
    Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
    J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Prognostic Significance of
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwińska-Jewsiewicka A; Wierzbicki PW; Kmieć Z
    Anticancer Res; 2017 Jun; 37(6):2927-2937. PubMed ID: 28551630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
    Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of MIR9‑3HG inhibits proliferation and promotes apoptosis of cervical cancer cells by miR‑498 via EP300.
    Li F; Liang Y; Ying P
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34468010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
    Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
    Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-βRII/EP300/SMAD4 cascade signaling pathway promotes invasion and glycolysis in oral squamous cell carcinoma.
    Zhang D; Peng Y; Lin G; Xiao Q; Liu H; Nan X; Han J; Zhao R; Wang Y; Liu J; Liu Y
    J Oral Pathol Med; 2023 Jul; 52(6):483-492. PubMed ID: 36916236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and analysis of human chordoma cell lines.
    Yang C; Hornicek FJ; Wood KB; Schwab JH; Choy E; Iafrate J; Rosenberg A; Nielsen GP; Xavier RJ; Mankin H; Duan Z
    Spine (Phila Pa 1976); 2010 Jun; 35(13):1257-64. PubMed ID: 20461036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.
    Li M; Shen Y; Xiong Y; Wang S; Li C; Bai J; Zhang Y
    Cell Prolif; 2021 Dec; 54(12):e13136. PubMed ID: 34668612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of survivin expression in 50 chordoma specimens--A histological and in vitro study.
    Froehlich EV; Rinner B; Deutsch AJ; Meditz K; Knausz H; Troppan K; Scheipl S; Wibmer C; Leithner A; Liegl B; Lohberger B
    J Orthop Res; 2015 May; 33(5):771-8. PubMed ID: 25640185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
    Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
    Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.